Aveo Pharmaceuticals, Inc.
AVEODrugs in Pipeline
8
Phase 3 Programs
5
Upcoming Catalysts
2
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
tivozanib (AV-951)
Advanced Renal Cell Carcinoma
Ficlatuzumab
Metastatic Head-and-neck Squamous-cell Carcinoma
Tivozanib
Renal Cell Carcinoma
Tivozanib hydrochloride
Carcinoma, Renal Cell
Samalizumab (BAML-16-001-S1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Tivozanib (1mg)
Advanced Adult Hepatocellular Carcinoma
AV-299 + gefitinib
Carcinoma, Non-Small Cell-Lung
mFOLFOX6
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
tivozanib (AV-951) | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Ficlatuzumab | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma | - | - |
Tivozanib | Phase 3 | Renal Cell Carcinoma | - | - |
Tivozanib hydrochloride | Phase 3 | Carcinoma, Renal Cell | - | - |
Samalizumab (BAML-16-001-S1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Tivozanib (1mg) | Phase 2 | Advanced Adult Hepatocellular Carcinoma | - | - |
AV-299 + gefitinib | Phase 2 | Carcinoma, Non-Small Cell-Lung | - | - |
mFOLFOX6 | Phase 2 | Colorectal Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aveo Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Aveo Pharmaceuticals, Inc.'s (AVEO) pipeline across Phase 3, Phase 2. Its lead program is tivozanib (AV-951) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aveo Pharmaceuticals, Inc.'s next FDA catalyst?→
Aveo Pharmaceuticals, Inc.'s (AVEO) next tracked catalyst is a Phase 2 expected November 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVEO biotech catalysts?→
Add AVEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aveo Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.